Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC.ASMB · Entity 5216 | Director | June 11, 2020 | June 15, 2020 |
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | Director | June 04, 2019 | June 06, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ASSEMBLY BIOSCIENCES, INC.
Report date June 11, 2020 · Filed June 15, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.47 · Expires 2030-06-11 | Direct | 10,000 |
Reported balance
After 2020-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-11 · Grant · Acquired 10,000 · Balance 10,000 F1: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 11, 2021 and (2) the date of the Issuer's 2021 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 11, 2021 and (2) the date of the Issuer's 2021 annual meeting of stockholders.
BIOMARIN PHARMACEUTICAL INC
Report date June 04, 2019 · Filed June 06, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,590 |
Reported balance
After 2019-06-04 transaction · row 1
1 source rowRow 1 · 2019-06-04 · Grant · Acquired 4,430 · Balance 25,590 F1: Restricted stock units granted on June 4, 2019. Price not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units granted on June 4, 2019. Price not applicable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2020 Filed Jun 15, 2020 20:43 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $20.47 | $0.00 |
DisclosureSEC source: 0001209191-20-036637 · doc4.xml · derivative · entry 1 LEWIS ALAN · CIK 0001207604 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-06-11 F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 11, 2021 and (2) the date of the Issuer's 2021 annual meeting of stockholders. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 21:55 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 4,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-012967 · doc1.xml · nonDerivative · entry 1 LEWIS ALAN · CIK 0001207604 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,590 F1 · price: Restricted stock units granted on June 4, 2019. Price not applicable. Read SEC document |
| May 17, 2019 Filed May 17, 2019 23:35 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $15.22 | $0.00 |
DisclosureSEC source: 0001144204-19-027160 · tv521926_4.xml · derivative · entry 1 LEWIS ALAN · CIK 0001207604 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-05-17 F1 · derivative.exercise_date: The shares of common stock underlying the option will vest upon the earlier of (i) May 17, 2020 and (ii) the date of the Issuer's 2020 annual meeting of stockholders. Read SEC document |
| August 28, 2018 Filed Aug 30, 2018 17:55 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 7,500 | $0.00 Strike: $14.39 | $0.00 |
DisclosureSEC source: 0001567619-18-001925 · doc1.xml · derivative · entry 4 LEWIS ALAN · CIK 0001207604 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2019-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| August 28, 2018 Filed Aug 30, 2018 17:55 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 200 | $99.12 | $19,824.00 |
DisclosureSEC source: 0001567619-18-001925 · doc1.xml · nonDerivative · entry 3 LEWIS ALAN · CIK 0001207604 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,160 Read SEC document |
| August 28, 2018 Filed Aug 30, 2018 17:55 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 7,300 | $99.11 | $723,503.00 |
DisclosureSEC source: 0001567619-18-001925 · doc1.xml · nonDerivative · entry 2 LEWIS ALAN · CIK 0001207604 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,360 Read SEC document |
| August 28, 2018 Filed Aug 30, 2018 17:55 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 7,500 | $14.39 | $107,925.00 |
DisclosureSEC source: 0001567619-18-001925 · doc1.xml · nonDerivative · entry 1 LEWIS ALAN · CIK 0001207604 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,660 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 21, 2018 Filed Aug 22, 2018 23:06 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 4,200 | $100.09 | $420,365.40 |
DisclosureSEC source: 0001567619-18-001677 · doc1.xml · nonDerivative · entry 1 LEWIS ALAN · CIK 0001207604 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,160 F1 · price: The price in column 4 is the weighted average price. The price actually received ranged from $100.07 to $100.11. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| June 05, 2018 Filed Jun 8, 2018 00:48 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 4,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-027793 · doc1.xml · nonDerivative · entry 1 LEWIS ALAN · CIK 0001207604 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,360 F1 · price: Restricted stock units granted on June 5, 2018. Price not applicable. F2 · balance_after: Amount of securities beneficially owned has been updated from the reporting person's prior report to exclude 5,000 shares inadvertently included in prior reports based on a reconciliation with the Company's records. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 21:46 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $42.09 | $0.00 |
DisclosureSEC source: 0001144204-18-032469 · tv495554_4.xml · derivative · entry 1 LEWIS ALAN · CIK 0001207604 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2028-05-30 F1 · derivative.exercise_date: The shares of common stock underlying the option will vest upon the earlier of (i) May 30, 2019 and (ii) the date of the Issuer's 2019 annual meeting of stockholders. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 22:27 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (right to buy) Common Stock · Derivative | 4,910 | $0.00 Strike: $89.60 | $0.00 |
DisclosureSEC source: 0001140361-17-024508 · doc1.xml · derivative · entry 2 LEWIS ALAN · CIK 0001207604 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,910 Underlying: Common Stock · 4,910 shares Expires 2027-06-05 F2 · derivative.exercise_date: Option grant vests in full on June 6, 2018. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 22:27 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 2,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-024508 · doc1.xml · nonDerivative · entry 1 LEWIS ALAN · CIK 0001207604 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,060 F1 · price: Restricted stock units granted on June 6, 2017. Price not applicable. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:31 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $25.96 | $0.00 |
DisclosureSEC source: 0001144204-17-031030 · v468316_4.xml · derivative · entry 1 LEWIS ALAN · CIK 0001207604 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2027-06-01 F1 · derivative.exercise_date: The shares of Common Stock underlying the option will vest upon the earlier of (i) June 1, 2018 and (ii) the date of the Issuer's 2018 annual meeting of stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.